Carisbamate vs Lamotrigine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline

Carisbamate

Developed by SK Biopharmaceuticals Co., Ltd.

Phase 3 in Epilepsysmall molecule
Partial signal

NCT00425282 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 study (study 1 of two identical trials) gave carisbamate 200 or 400 mg/day or placebo for 12 weeks to 565 adults with refractory partial-onset seizures. The registered primary endpoint was the change in partial-onset seizure frequency. The 400 mg/day dose met it (median reduction 27.27% vs 15.21% with placebo, P = 0.009, and the paper reports the responder rate was also significant at this dose), while 200 mg/day did not differ from placebo (P = 0.678). The primary endpoint was met at the higher dose and missed at the lower dose, so the result is mixed. Sources: EU Clinical Trials Register results (EudraCT 2006-003839-68) and Sperling et al., Epilepsia 2010.

Next expected readout: February 2027 · NCT05219617 (registry estimate)

Reported efficacy

The primary outcome is the change in seizure frequency of all simple partial motor, complex partial, or secondarily generalized seizures from the pretreatment baseline phase compared with the double-blind treatment phase.: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results). (mixed)

Result source: NCT00425282

Lamotrigine

Marketed by GlaxoSmithKline

Approved in Epilepsysmall molecule
Weak signal

NCT01431976 · Phase 3 · completed

This was a small, single-arm, open-label study of 20 participants, with no randomization, blinding, or comparator. The primary clinical endpoint found 7 of 20 participants (35%) seizure free by hyperventilation-EEG at the end of maintenance, but there was no formal between-group comparison.

Reported efficacy

Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 (missed)

Result source: NCT00088452

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCarisbamateLamotrigine
Seizure frequency, % change—Not posted · NCT0043366775.4% vs 32.1%+43.3 vs placebowk 19 · n 69NCT00104416
50% responder rate—Not posted · NCT00433667—Not posted · NCT00007670
Seizure freedom—Not posted · NCT00433667—Not posted · NCT00007670

Seizure frequency, % change

Carisbamate
—Not posted · NCT00433667
Lamotrigine
75.4% vs 32.1%+43.3 vs placebowk 19 · n 69NCT00104416

50% responder rate

Carisbamate
—Not posted · NCT00433667
Lamotrigine
—Not posted · NCT00007670

Seizure freedom

Carisbamate
—Not posted · NCT00433667
Lamotrigine
—Not posted · NCT00007670
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Carisbamate
Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results). NCT00425282 · Phase 3 · design grade: moderate · publication or press release
Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). NCT00433667 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Carisbamate: 0 of 4 rows · Lamotrigine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLamotrigine
Dropout rate
70%a
NCT01431976 · Phase 3 · monotherapy
show 16 more results
0%
NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3
—
NCT02404168 · Phase 4 · registry result, not featured evidence
—
NCT01995825 · Phase 4 · registry result, not featured evidence
52.2%
NCT01431963 · Phase 3 · registry result, not featured evidence
—
NCT00516139 · Phase 3 · registry result, not featured evidence
20%
NCT00292461 · Phase 3 · registry result, not featured evidence
3.9%Adolescents: LTG
NCT00395694 · Phase 3 · registry result, not featured evidence
2%Adults: LTG
NCT00395694 · Phase 3 · registry result, not featured evidence
—300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
16.8%300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
—300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
30.1%250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
—250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
13.2%
NCT00104416 · Phase 3 · registry result, not featured evidence
0%
NCT00789113 · Phase 1/2 · registry result, not featured evidence
—
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
Discontinued due to AEs
30%a
NCT01431976 · Phase 3 · monotherapy
show 16 more results
—
NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3
—
NCT02404168 · Phase 4 · registry result, not featured evidence
—
NCT01995825 · Phase 4 · registry result, not featured evidence
26.9%
NCT01431963 · Phase 3 · registry result, not featured evidence
—
NCT00516139 · Phase 3 · registry result, not featured evidence
6.7%
NCT00292461 · Phase 3 · registry result, not featured evidence
3.9%Adolescents: LTG
NCT00395694 · Phase 3 · registry result, not featured evidence
2%Adults: LTG
NCT00395694 · Phase 3 · registry result, not featured evidence
—300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
3.5%300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
—300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
8.8%250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
—250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
1.3%
NCT00104416 · Phase 3 · registry result, not featured evidence
—
NCT00789113 · Phase 1/2 · registry result, not featured evidence
—
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
Serious AEs
0%a
NCT01431976 · Phase 3 · monotherapy
show 16 more results
1.3%
NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3
0%
NCT02404168 · Phase 4 · registry result, not featured evidence
0%
NCT01995825 · Phase 4 · registry result, not featured evidence
12.3%
NCT01431963 · Phase 3 · registry result, not featured evidence
18.2%
NCT00516139 · Phase 3 · registry result, not featured evidence
3.3%
NCT00292461 · Phase 3 · registry result, not featured evidence
3.9%Adolescents: LTG
NCT00395694 · Phase 3 · registry result, not featured evidence
9.8%Adults: LTG
NCT00395694 · Phase 3 · registry result, not featured evidence
1.6%300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
—300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
2.7%300 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
—250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
4.5%250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence
1.4%
NCT00104416 · Phase 3 · registry result, not featured evidence
0%
NCT00789113 · Phase 1/2 · registry result, not featured evidence
0%
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
Most frequent reported AEs
a
nasopharyngitis 35%
rash 30%
bronchitis 25%
NCT01431976 · Phase 3 · monotherapy
show 13 more results
fatigue 8.7%
headache 8.1%
hostility 6.7%
NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3
dizziness 50%
headache 50%
NCT02404168 · Phase 4 · registry result, not featured evidence
headache 11.4%
dizziness 5.7%
blurred vision 2.9%
NCT01995825 · Phase 4 · registry result, not featured evidence
nasopharyngitis 23.1%
headache 21.5%
rash 12.3%
NCT01431963 · Phase 3 · registry result, not featured evidence
dizziness 25.6%
balance disorder 20.7%
fall 18.2%
NCT00516139 · Phase 3 · registry result, not featured evidence
diplopia 10%
dizziness 6.7%
insomnia 6.7%
NCT00292461 · Phase 3 · registry result, not featured evidence
upper respiratory tract inflammation 29.4%
nasopharyngitis 27.5%
diarrhoea 21.6%
NCT00395694 · Phase 3 · registry result, not featured evidence
dizziness 19.6%
nasopharyngitis 19.6%
contusion 15.7%
NCT00395694 · Phase 3 · registry result, not featured evidence
300 mg
headache 17.9%
dizziness 6%
nausea 3.3%
NCT00355082 · Phase 3 · registry result, not featured evidence
300 mg
headache 25.9%
dizziness 10.7%
nasalpharyngitis 6.3%
NCT00355082 · Phase 3 · registry result, not featured evidence
250 mg
headache 27.9%
rash 10.8%
dizziness 9%
NCT00355082 · Phase 3 · registry result, not featured evidence
headache 13.9% (placebo 16.2%)
vomiting 9.7% (placebo 4.1%)
nausea 6.9% (placebo 5.4%)
NCT00104416 · Phase 3 · registry result, not featured evidence
somnolence 80%
dizziness 66.7%
headache 60%
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy

Notes

  1. aPopulation comparability has not been reviewed for 16 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lamotrigine

Seizure-free 35% (n=20) @ 50wk
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT01431976 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
show 2 more results
100% (n=7) @ 4wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
100% (n=7) @ 8wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
Seizure-free 24.7% (n=89) @ 23wk300 mg
responder rate · % of participants
No placebo or comparator arm
NCT00355082 · Phase 3 · registry result, not featured evidence · converted to % from 22 participants as posted
show 2 more results
10.5% (n=76) @ 23wk*250 mg
NCT00355082 · Phase 3 · registry result, not featured evidence · converted to % from 8 participants as posted
40% (n=20)*
NCT01431976 · Phase 3 · monotherapy · converted to % from 8 Participants as posted
Seizure-free 30% (n=20) @ 12wk
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
show 13 more results
25% (n=20) @ 36wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 5 Participants as posted
30% (n=20) @ 60wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
30% (n=20) @ 84wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
30% (n=20) @ 108wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
30% (n=20) @ 132wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
10% (n=20) @ 156wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 2 Participants as posted
25% (n=20) @ 24wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 5 Participants as posted
30% (n=20) @ 48wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
25% (n=20) @ 72wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 5 Participants as posted
30% (n=20) @ 96wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 6 Participants as posted
25% (n=20) @ 120wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 5 Participants as posted
10% (n=20) @ 144wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 2 Participants as posted
5% (n=20) @ 168wk*
NCT01431976 · Phase 3 · monotherapy · converted to % from 1 Participants as posted
Seizure Days Per 0.1 months
absolute value · months
Maintenance
No placebo or comparator arm
FEP+EP+MP, n=20
NCT01431976 · Phase 3 · monotherapy · converted to months from 2.98 days as posted
Seizure Days Per 0 months
absolute value · months
Extension (open-label)
No placebo or comparator arm
NCT01431976 · Phase 3 · monotherapy · converted to months from 0.03 days as posted
Treatment Failure Free 29.5% (n=146) vs 58.2% (n=146) Valproic Acid @ 20wk
event count · % of participants
NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 · converted to % from 43 Participants as posted
show 1 more result
21.2% (n=146) vs 43.8% (n=146) Valproic Acid @ 52wk*
NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 · converted to % from 31 Participants as posted
Seizure Free 6 43.1% (n=65) @ 30wk
event count · % of participants
Maintenance
No placebo or comparator arm
All, n=65
NCT01431963 · Phase 3 · registry result, not featured evidence · converted to % from 28 participants as posted
Time to First Seizure 3.38 months @ 30wk
time to event · months
Maintenance
No placebo or comparator arm
All, n=52
NCT01431963 · Phase 3 · registry result, not featured evidence · converted to months from 103 days as posted
Partial Seizure Frequency 97.8% (n=55) @ 7wk
percent change · % of baseline
Maintenance
No placebo or comparator arm
Dose-Escalation Phase (Week 7), n=55
NCT00516139 · Phase 3 · registry result, not featured evidence
Partial Seizure Frequency 100% (n=55) @ 15wk
percent change · % of baseline
Maintenance
No placebo or comparator arm
Maintenance Phase (Week 15), n=43
NCT00516139 · Phase 3 · registry result, not featured evidence
Partial Seizure Frequency 90.4% (n=55)
percent change · % of baseline
Maintenance
No placebo or comparator arm
End Of Treatment (Week 30/33), n=55
NCT00516139 · Phase 3 · registry result, not featured evidence
Seizure-free 80.3% (n=66)
event count · % of participants
No placebo or comparator arm
Remained Seizure-Free
NCT00516139 · Phase 3 · registry result, not featured evidence · converted to % from 53 participants as posted

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carisbamate's landscape · Lamotrigine's landscape